Compare GAM & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GAM | NUVB |
|---|---|---|
| Founded | 1927 | 2018 |
| Country | United States | United States |
| Employees | N/A | 298 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | N/A | N/A |
| Metric | GAM | NUVB |
|---|---|---|
| Price | $64.11 | $5.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.38 |
| AVG Volume (30 Days) | 30.0K | ★ 2.9M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 5.74% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 11.67 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $203.82 |
| Revenue Next Year | N/A | $58.18 |
| P/E Ratio | $5.49 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $47.73 | $1.57 |
| 52 Week High | $64.42 | $9.75 |
| Indicator | GAM | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 72.27 | 62.11 |
| Support Level | $62.22 | $4.06 |
| Resistance Level | $64.28 | $5.55 |
| Average True Range (ATR) | 0.94 | 0.24 |
| MACD | 0.53 | 0.11 |
| Stochastic Oscillator | 95.52 | 91.51 |
General American Investors Co Inc is a closed-end, diversified management investment company. The primary investment objective of the company is long-term capital appreciation through investment in companies with above-average growth potential. It focuses on equity securities with growth potential at reasonable valuations. The company invests principally in common stocks believed by management to have growth potential.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.